Pharma and Biotech Daily: Your Essential Guide to Industry Updates

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.On August 19, 2024, the FDA approved the first at-home syphilis test by NowDiagnostics, providing quick results with just a drop of blood. Dupont acquired Donatelle Plastics for $313 million, while Boston Scientific resubmitted its merger filing for Silk Road Medical. Edwards invested in Genesis Medtech and Biden pledged $150 million for medical technology to enhance cancer surgery. The biotech industry is active, with companies gearing up for the DSCSA deadline and utilizing multiple trial technologies. In the biopharma industry, Bristol Myers' schizophrenia drug is nearing approval, a partial hold was lifted on a Biontech-partnered ADC study, Novo Nordisk plans to build a new plant, and Medicare drug price cuts are impacting pharma profits. Patient-centric commercialization strategies are on the rise, along with concerns about Medicare price cuts affecting drug research and patent protection measures.Bristol Myers Squibb's KarXT faces a PDUFA date for potential approval as a new schizophrenia treatment. AbbVie's Emraclidine also shows promise as a gut-friendly option for schizophrenia patients. Market strategies beyond FDA approval are being explored to ensure successful drug launch and adoption in the competitive landscape.The FDA has cleared Biontech-Medilink's Phase I ADC cancer trial after a partial hold, while Liquidia missed full approval for a pulmonary hypertension drug. Bavarian Nordic is ramping up vaccine production in response to a global health emergency. Developers remain optimistic about psychedelic therapies despite setbacks like Lykos' rejection. Other updates include advancements in various therapeutic spaces and industry shifts such as layoffs.Texas hospitals secured a victory in a lawsuit on low-income payment formulas. Employer healthcare costs are expected to rise due to inflation and specialty drugs. Healthcare bankruptcies have slowed down but financial challenges persist. Payers are leveraging digital technology to improve outcomes and prepare for regulatory changes like the DSCSA deadline. Healthcare organizations are focusing on patient-centric care, combating burnout, and adapting to trends like telehealth and value-based care.In conclusion, the Pharma and Biotech industry is evolving rapidly with advancements in technology, regulatory changes, and shifting market dynamics shaping its future trajectory. Stay tuned for more updates on the latest developments in this dynamic sector.